• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How Investors Are Reacting To Krystal Biotech (KRYS) Earnings Beat And Buyback

    Simply Wall St·11/05/2026 05:29:19
    Listen to the news
    • Krystal Biotech reported Q3 2026 net income of US$63.07 million and diluted EPS of US$2.05, alongside a new US$400 million share repurchase authorization with no expiry.
    • Management is pairing Vyjuvek driven earnings strength with a sizable buyback at the same time some clinical readouts are now scheduled for 2027, which sharpens the trade off between current cash generation and pipeline timing.
    • We will look at how Krystal Biotech's investment narrative is affected by the new US$400 million buyback alongside pipeline timing shifts.

    Compare Krystal Biotech's mix of earnings strength and buybacks with other potential opportunities by scanning our curated list of 19 high quality undiscovered gems in similar high-upside niches.

    Krystal Biotech Investment Narrative Recap

    To own Krystal Biotech, you need to be comfortable with a rare disease cash engine in Vyjuvek and a broad HSV 1 platform that is still in development. The big operational swing factor in the near term remains execution on ex US Vyjuvek rollout and pricing, especially in Europe where negotiations can pressure reported margins.

    The sharpest risk right now is that delayed readouts for ophthalmology and other programs stretch the timeline for Krystal Biotech to become a true multiproduct enterprise while R&D and commercial spend keep climbing. The latest quarter does not appear to change that equation materially; it just highlights timing friction between earnings today and pipeline progress.

    The fresh US$400 million share repurchase authorization sits squarely in that tension. Management is signaling comfort deploying a sizable pool of capital into Krystal Biotech equity while the market processes an 11% share price drop on the day of the release and slower trial enrollment in neurotrophic keratitis.

    For you, the key question is how that buyback interacts with the catalyst path. If Vyjuvek demand and international launch work continue to support cash generation, repurchases can concentrate exposure to future KB803, KB801 and KB707 outcomes. If pricing pressure or trial delays deepen, the same buyback simply amplifies execution risk on a smaller base of products.

    Krystal Biotech's current analyst narrative points to US$1.3b of revenue and US$772.0 million of earnings by 2029. This is based on an assumed 43.6% yearly increase in revenue and an earnings step up of about US$530 million from US$241.5 million today.

    Uncover why Krystal Biotech's fair value indicates a 26% potential upside to its current price that could narrow quickly.

    NasdaqGS:KRYS 1-Year Stock Price Chart
    NasdaqGS:KRYS 1-Year Stock Price Chart

    Exploring Other Perspectives

    Some bullish analysts focus on the KB803 ocular DEB catalyst rather than the new buyback. They had been pencilling in revenues of about US$1.8b and earnings of roughly US$1.1b by 2029, far above consensus. Those views were set before this Q3 report and repurchase plan, so forecasts may shift as opinions reset.

    Explore 4 other Krystal Biotech fair value estimates, including one that suggests up to 455% upside from the current price!

    Form Your Own Verdict

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider conducting your own research and forming your own view.

    Looking For More Investment Ideas Beyond Krystal Biotech?

    Once you have a view on Krystal Biotech, it can help to widen the lens and compare it with other companies that fit different risk and return profiles. The Simply Wall St Screener can surface stocks with very different strengths so you are not relying on a single story.